Navigation Links
Favrille Announces $21.1 Million Registered Direct Offering
Date:11/2/2007

EF="http://www.sec.gov" target="_new">http://www.sec.gov or from Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. To receive additional information on the Company, please visit our website at http://www.favrille.com. Information on our website does not, however, form a part of this press release.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected closing date for the financing, Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to whether the offering will close when expected or at all; progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, ma
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... GERMANTOWN, Md. , June 29, 2015  Neuralstem, ... stem cell technology to develop small molecule and cell ... that it has been approved for listing on the ... common stock will continue to trade on the NYSE ... Trading on the NASDAQ Capital Market is expected to ...
(Date:6/29/2015)... Calif. , June 29, 2015   Veracyte, ... company pioneering the field of molecular cytology, today announced ... News Group,s prestigious Top Workplaces list for the second ... Workplace winners based solely on an annual survey of ... and honored that the degree to which Veracyte values ...
(Date:6/26/2015)... 26, 2015  SeraCare Life Sciences, a leading ... announced that it has signed a Cooperative Research ... Institute (NCI), part of the National Institutes of ... for cancer assays.  The CRADA will investigate the ... control DNA biosynthetics spiked into a genomic DNA ...
(Date:6/26/2015)... ... June 26, 2015 , ... Charm Sciences, Inc. is pleased ... Stockyards Administration (GIPSA) awarded a five year contract to Charm Sciences to monitor ... ROSA DONQ-FAST5 Test. This 5 minute quantitative test extracts DON from samples using ...
Breaking Biology Technology:Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2
... Companies will Present at the Largest Marketplace for Emerging ... and CTSI today announced that more than 100 leading ... partners will be showcased in the 4th Annual TechConnect ... R. Brown Convention Center in Houston, Texas. Held ...
... Development and InnovationMOUNTAIN VIEW, Calif., April 22 ... Pharmaceuticals & Biotechnology group assesses a variety of ... in cancer treatment. Physicians, nurses and patients ... reconstitution, home vs. office administration parameters, and barriers ...
... 22 GeneGo, Inc., a leading provider of software ... , today announced that the University of Cardiff has ... researchers will have access to GeneGo,s MetaCore, training and ... their partner relationship with GeneGo to provide a pathway ...
Cached Biology Technology:TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3Cardiff University Becomes a GeneGo Center of Excellence 2
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... Jos Zanchetta, a member of the IOF Board and ... has been named the recipient of the prestigious Pierre ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ... growth of the Foundation and osteoporosis advocacy worldwide. ...
... the damage caused by a heart attack survived in the ... a mouse model, researchers at The University of Texas MD ... Circulation Research . The study, with researchers at the ... imaging techniques developed by researchers at MD Anderson to track ...
... a 1600 km-wide ash cloud over the Atlantic. The ... visible in stark contrast to white clouds framing this ... emitting steam and ash on 20 March, wreaking havoc ... week caused some flights to be suspended to and ...
Cached Biology News:Transplanted adult stem cells provide lasting help to injured hearts 2Transplanted adult stem cells provide lasting help to injured hearts 3Transplanted adult stem cells provide lasting help to injured hearts 4
...
cysteine and glycine-rich protein 2,...
... agent and DNA-topoisomersae II inhibitor (IC50 = 59.2 ... C 29 H 32 O 13 ... Store at: RT ... Soluble to 100 mM ...
HSPBP1 Antibody...
Biology Products: